Prognostic Value of uPA and PAI-1 and PAI-2 in Breast Cancer
Author Information
Author(s): C. Bouchet, F. Spyratos, P.M. Martin, K. Hacene, A. Gentile, J. Oglobin
Primary Institution: Centre Rene Huguenin
Hypothesis
The study aims to analyze the prognostic value of urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in breast cancer.
Conclusion
High levels of PAI-1 and low levels of PAI-2 are associated with poor prognosis in breast cancer patients, particularly in post-menopausal women.
Supporting Evidence
- Univariate analysis confirmed that high levels of uPA and PAI-1 correlate with poor outcomes.
- Low levels of PAI-2 were associated with shorter disease-free survival.
- Multivariate analysis identified node involvement, macroscopic tumor size, and PAI-2 as significant variables.
Takeaway
This study found that certain proteins in breast cancer can help predict how well patients will do, with some levels indicating a higher risk of problems.
Methodology
The study used an immunoenzymatic method to measure uPA, PAI-1, and PAI-2 levels in cytosols from 314 primary breast tumors and followed patients for a minimum of 6 years.
Limitations
The study may have limitations related to the specific population and treatment regimens, which could affect the generalizability of the results.
Participant Demographics
The mean age of participants was 55 years, with a range from 30 to 86 years; 59% underwent total mastectomy and 41% partial mastectomy.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website